SavedAdd your journal

Journals / Klimik Dergisi / 2011 / Cilt: 24 - Sayı: 2

Pegylated interferon and ribavirin treatment of chronic hepatitis C coinfection in a patient with human immunodeficiency virus infection

İnsan immün yetmezlik virusuyla infekte bir olguda kronik hepatit C koinfeksiyonunun pegile interferon ve ribavirinle sağaltımı

Nejat Ali COŞKUN
Can Hüseyin HEKİMOĞLU
Aslı Gamze ŞENER
Nesrin TÜRKER
Sibel EL
Serap URAL
İlknur VARDAR
Bahar ÖRMEN
Figen KAPTAN
Pages
122–125
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

During the course of CHC treatment no adverse effect was seen.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection is seen frequently due to similar routes of transmission.
📊
Key Findings & Data:In coinfected patients, progression of chronic hepatitis C (CHC) infection is accelerated.
💡
Conclusion & Impact:During the course of CHC treatment no adverse effect was seen.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection is seen frequently due to similar routes of transmission. In coinfected patients, progression of chronic hepatitis C (CHC) infection is accelerated. In this study, a 44-year old male patient with HIV/HCV (genotype 1b) coinfection is evaluated. For the treatment of CHC, pegylated interferon alpha 2a 180 mg per week and ribavirin 1000 mg/day were used for 48 weeks and sustained virologic response was achieved. During the course of CHC treatment no adverse effect was seen.

Özet

İnsan immün yetmezlik virusu (HIV) ve hepatit C virusu (HCV) koinfeksiyonu bulaşma yollarının benzer olması nedeniyle sık görülmektedir. Koinfekte hastalarda kronik hepatit C (KHC) infeksiyonunun progresyonu hızlanmaktadır. Bu çalışmada HIV/ HCV (genotip 1b) koinfeksiyonu saptanan 44 yaşındaki erkek hasta değerlendirilmiştir. KHC tedavisi için 48 hafta süreyle pegile interferon alfa 2a 180 mg haftada bir ve ribavirin 1000 mg/ gün kullanılmış ve kalıcı virolojik yanıta ulaşılmıştır. KHC tedavisi sırasında herhangi bir yan etki gözlenmemiştir.

🔖

Cite This Article

COŞKUN, N. A., HEKİMOĞLU, C. H., ŞENER, A. G., TÜRKER, N., EL, S., URAL, S., VARDAR, İ., ÖRMEN, B., KAPTAN, F. (2022). Pegylated interferon and ribavirin treatment of chronic hepatitis C coinfection in a patient with human immunodeficiency virus infection. Klimik Dergisi, Cilt: 24 - Sayı: 2, 122–125. https://ajindex.com/articles/573686

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Wasmuth JC, Rockstroh J. HIV and HBV/HCV coinfections. In: Hoffmann C, Rockstroh JK, eds. HIV 2010. Hamburg: Medizin Fokus Verlag, 2010: 490-506
  2. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology. 2002; 36(Suppl. 1): S201-9. [Crossref] 3. Erbay A, Bodur H, Çolpan A, Akıncı E, Korkmaz M, Eren Ş. HIV/ AIDS olgularının değerlendirilmesi. Türk HIV/AIDS Derg. 2003; 6(2): 43-6
  3. Ural S, Kaptan F, Türker N, et al. İnsan immün yetmezlik virusuyla infekte olgularda hepatit B virusu ve hepatit C virusu infeksiyonu seroprevalansı. Klimik Derg. 2010; 23(3): 100-4. [Crossref] 5. Sayın Kutlu S, Çelikbaş AK, Eren Ş, Kutlu M, Motor VK, Dokuzoğuz B. HIV infekte olguların hepatit B ve hepatit C ile birlikteliği. Türk HIV/AIDS Derg. 2003; 6(1): 11-6
  4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999; 30(4): 1054-8. [Crossref] 7. Martín-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004; 38(1): 128-33. [Crossref] 8. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000; 283(1): 74-80. [Crossref] 9. Núñez M, Lana R, Mendoza JL, Martín-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 27(5): 426-31. [Crossref] 10. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44(1 Suppl.): S6-9. [Crossref] 11. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13): 853-60. [Crossref] 12. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001; 32(3): 492-7. [Crossref] 13. Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 200